Artiva Biotherapeutics Files Q1 2025 10-Q
Ticker: ARTV · Form: 10-Q · Filed: May 8, 2025 · CIK: 1817241
| Field | Detail |
|---|---|
| Company | Artiva Biotherapeutics, Inc. (ARTV) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotechnology, licensing-agreement, financial-results
TL;DR
Artiva Biotherapeutics filed its Q1 2025 10-Q, showing operational updates and financial status.
AI Summary
Artiva Biotherapeutics, Inc. filed a 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its business operations. Key agreements mentioned include the Carnot Services Agreement and the Option and License Agreement for AB-201 Selected Product with GC Cell.
Why It Matters
This filing provides investors with a quarterly update on Artiva's financial health and operational progress, including details on key licensing and service agreements.
Risk Assessment
Risk Level: medium — As a biotechnology company, Artiva Biotherapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Artiva Biotherapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- Carnot Services Agreement (contract) — Key agreement mentioned
- Option and License Agreement for AB-201 Selected Product (contract) — Key agreement mentioned
- GC Cell (company) — Party to an agreement with Artiva
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the first quarter of 2025, ending on March 31, 2025.
What are some of the key agreements mentioned in the filing?
The filing mentions the Carnot Services Agreement and the Option and License Agreement for AB-201 Selected Product, as amended, with GC Cell.
What is Artiva Biotherapeutics, Inc.'s primary business sector?
Artiva Biotherapeutics, Inc. is in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector, SIC code 2836.
Where is Artiva Biotherapeutics, Inc. located?
Artiva Biotherapeutics, Inc. is located in San Diego, CA, with its business and mailing address at 5505 Morehouse Drive, San Diego, CA 92121.
What is the SEC file number for this filing?
The SEC file number for this filing is 001-42179.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Artiva Biotherapeutics, Inc. (ARTV).